Clinical Trials
676 trialsSTARTRK-2
Hoffmann-La Roche
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
RAINFOL-01
Genmab
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
RSPH5973-23
Emory University
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
National Institutes of Health Clinical Center (CC)
VERDI
Dana-Farber Cancer Institute
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
M.D. Anderson Cancer Center
PIKALO-1
Eli Lilly and Company
EXCEED
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
FiREBOLT
Eli Lilly and Company
DESCENT-1
A2 Biotherapeutics Inc.
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
Stanford University
TTBF
University of California, San Francisco
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
AstraZeneca
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
New Phase Ltd.
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
N01-A-PICIT-GT
Peking University People's Hospital
DIALOGUE
University of Basel
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
AstraZeneca
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
LONGEVITI
University of Alberta
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
National Institutes of Health Clinical Center (CC)
panSOHO
Bayer
PANEL
University Hospital, Rouen
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
FHAMe
University of Toronto
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Unity Health Toronto
iCaRe2
University of Nebraska
CERTIS1
AstraZeneca
REFLECT
University Health Network, Toronto
LEAP-005
Merck Sharp & Dohme LLC
BASECAMP-1
A2 Biotherapeutics Inc.